Therefore, the inhibition of E2F-DNMT1 axis by CDK-i administration acts on one side on tumor cells, making them more antigenic, but, on the other, also on T-reg cells in tumor microenvironment, reducing their number by increasing p21 expression (94). The gene discussed is DNMT1; the disease is neoplasm.